Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α vβ 3-Targeted Radiotracer 99mtc-3P-RGD 2

Theranostics

Volumn 2, Issue 6, 2012, Pages 577-588

  Zhou, Yang ^a   Shao, Guoqiang ^a,b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

99mtc 3P RGD 2; Breast cancer lung metastasis; U SPECT II CT

Indexed keywords

ARGININE GLYCINE ASPARTIC ACID TC 99M; RADIOISOTOPE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER GROWTH; FEMALE; ISOTOPE LABELING; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; RADIATION MONITORING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR NECROSIS;

EID: 84864400964     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4443     Document Type: Article

References (41)

1. Fantozzi A, Christofori G. Mouse models of breast cancer metasta-sis. Breast Cancer Res 2006; 8: 212-222.
2. Kim IS, Baek SH. Mouse models for breast cancer metastasis. Bio-chem Biophys Res Commun 2010; 394: 443-447.
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
4. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
5. Kaijzel EL, van der Pluijm G, Löwik CW. Whole-body optical im-aging in animal models to assess cancer development and progres-sion. Clin Cancer Res 2007; 13: 3490-3497.
6. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massagué J. Distinct or-gan-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
7. Zhao D, Richer E, Antich PP, Mason RP. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J 2008, 22: 2445-2451.
8. 18F-labeled affibody molecules. J Nucl Med 2009; 50: 1131-1139.
9. Gonda K, Watanabe TM, Ohuchi N, Higuchi H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells us-ing quantum dots. J Biol Chem 2010; 285: 2750-2757.
10. Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2-response to therapy, other indications, and future directions. J Nucl Med 2009; 50: 738-748.
11. Bestic JM, Peterson JJ, Bancroft LW. Use of FDG PET in staging, restaging, and assessment of therapy response in Ewing sarcoma. RadioGraphics 2009; 29: 1487-1501.
12. 3 for angiogenesis. Science 1994; 264: 569-571.
13. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological impli-cations and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
14. Felding-Habermann B, O';Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 1853-1858.
15. 5 integrin expression in glioma periphery. Neurosurgery 2001; 49: 380-389.
16. Smythe WR, LeBel E, Bavaria JE, Kaiser LR, Albelda SM. Integrin expression in non-small cell carcinoma of the lung. Cancer Metas-tasis Rev 1995; 14: 229-239.
17. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angio-genesis correlates with metastatic disease, N-myc-amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 405-414.
18. 3 integrin and intercellular adhesion molecule-1 ex-pression in cutaneous malignant melanoma lesions. Cancer Res 1997; 57: 1554-1560.
19. 3 integrin receptors in breast tumor. J Exp Clin Cancer Res 2001; 20: 585-590.
20. 3 correlates with actin cyto-skeleton in primary cultures of human breast cancer. Cancer Cell Int 2007; 7: 16-26.
21. 3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006; 8: R20.
22. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002; 16: 1266-1268.
23. Zitzmann S, Ehemann V, Schwab M. Arginine-Glycine-Aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res 2002; 62: 5139-5143.
24. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009; 20: 2199-2213.
25. Zhou Y, Chakraborty S, and Liu S. Radiolabeled cyclic RGD pep-tides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics, 2011; 1: 58-82.
26. Liu Z, Fan Wang F, Chen X. Integrin targeted delivery of radio-therapeutics. Theranostics, 2011; 1: 201-210
27. Cai W, Chen X. Multimodality molecular imaging of tumor angio-genesis. Nucl Med 2008; 49: 113S-128S.
28. 18F]Galacto-RGD. PLoS Med 2005; 2: e70.
29. 3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255-259.
30. 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49: 879-886.
31. 99mTc-NC100692. J Nucl Med 2006; 47: 1434-1439.
32. 4 linkers. Mol Pharm 2009; 6: 231-245.
33. 2 in non-human primates. Mol Imaging Biol 2010; 13: 730-736.
34. 2 scintigraphy. Eur J Nucl Med Mol Imaging 2011; 38: 2145-2152.
35. 3 expression. Mol Imaging 2011; 10: 386-397.
36. Shao G, Zhou Y, Wang F, Liu S. Monitoring glioma growth and tumor necrosis with u-SPECT-II/CT by targeting integrin αvβ3. Mol Imaging 2012; accepted.
37. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-424.
38. Gay LJ, Felding-Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer 2011; 11: 123-134.
39. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-2658.
40. Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A, Watson PH. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 2003; 81: 61-69.
41. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 2011; 7: 1223-1235.